Case Report: Semaglutide-associated depression: a report of two cases
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Semaglutide, as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was approved for glucose control in type 2 diabetes mellitus in 2017 and approved for weight loss in 2021 by the U.S. Food and Drug Administration (FDA). No psychiatric adverse effect associated with semaglutide has been reported so far. Here we report two cases of semaglutide-associated depression. One is a middle-aged man with no previous history of depression who developed depressive symptoms about 1 month after taking semaglutide. The other one is a middle-aged woman with recurrent depressive disorder whose symptoms also recurred about 1 month after semaglutide treatment. Depression was improved or relieved after discontinuation of semaglutide in both cases. Possible psychiatric adverse effects of depression should be taken into consideration when semaglutide is administered to patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“concerns regarding a possible link between semaglutide use and depressive symptoms and suicidal ideation have recently emerged through case reports [91].”
From What Is Food Noise? A Conceptual Model of Food Cue Reactivity (2023) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Epidemiology and determinants of obesity in China
Pan, X.-F., Wang, L., & Pan, A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00045-0 · Cited by 1,554
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970 · cited 1×
“As a long acting GLP-1 RA, semaglutide can translocate to the brain stem, lateral septum (LS), and hypothalamus, interact directly with various GLP-1 receptor subtypes and modulate the activity of neural pathways involved in food intake, reward, and energy expenditure (19, 20).”
BackgroundO'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717 · cited 1×
“As a long acting GLP-1 RA, semaglutide can translocate to the brain stem, lateral septum (LS), and hypothalamus, interact directly with various GLP-1 receptor subtypes and modulate the activity of neural pathways involved in food intake, reward, and energy expenditure (19, 20).”
BackgroundGlucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Dopamine promotes cognitive effort by biasing the benefits versus costs of cognitive work
Westbrook, A., van den Bosch, R., Määttä, J. I., Hofmans, L., Papadopetraki, D., Cools, R., & Frank, M. J. (2020) · Science · doi:10.1126/science.aaz5891 · Cited by 356
The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Klausen, M. K., Thomsen, M., Wortwein, G., & Fink‐Jensen, A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15677 · Cited by 259 · cited 1×
“Studies in rodents and non-human primates have demonstrated that GLP-1 RAs can lead to a reduction in the intake of alcohol and drugs of abuse (15).”
Background
Cited by
Kornelius, E., Huang, J.-Y., Lo, S.-C., Huang, C.-N., & Yang, Y.-S. (2024) · Scientific Reports · doi:10.1038/s41598-024-75965-2 · Cited by 143
“Li et al. reported two cases of depression associated with the use of semaglutide 19 .”
BackgroundZhou, J., Zheng, Y., Xu, B., Long, S., Zhu, L.-E., Liu, Y., Li, C., Zhang, Y., Liu, M., & Wu, X. (2024) · BMC Medicine · doi:10.1186/s12916-024-03274-6 · Cited by 82
What Is Food Noise? A Conceptual Model of Food Cue Reactivity
Hayashi, D., Edwards, C., Emond, J. A., Gilbert-Diamond, D., Butt, M., Rigby, A., & Masterson, T. D. (2023) · Nutrients · doi:10.3390/nu15224809 · Cited by 80
“Additionally, concerns regarding a possible link between semaglutide use and depressive symptoms and suicidal ideation have recently emerged through case reports [91].”
BackgroundDe Giorgi, R., Ghenciulescu, A., Dziwisz, O., Taquet, M., Adler, A. I., Koychev, I., Upthegrove, R., Solmi, M., McCutcheon, R., Pillinger, T., et al. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00390-x · Cited by 77
The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review
Valenta, S. T., Nicastri, A., Perazza, F., Marcolini, F., Beghelli, V., Atti, A. R., & Petroni, M. L. (2024) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-024-00331-y · Cited by 55
Lu, W., Wang, S., Tang, H., Yuan, T., Zuo, W., & Liu, Y. (2025) · European Psychiatry · doi:10.1192/j.eurpsy.2024.1803 · Cited by 48
Kerem, L., & Stokar, J. (2024) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2024.3812 · Cited by 47
Mental Health Implications of Weight Loss Medications: A Narrative Review
Harding, S. (2024) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2024.105207 · Cited by 44
Meshkat, S., Luciano, C. D., Swiderski, A., Li, G., Aguilar, R. J., Dunkley, B. T., Reichelt, A. C., Zhang, Y., Greenshaw, A. J., Vermetten, E. H. G. J. M., et al. (2025) · Brain and Behavior · doi:10.1002/brb3.70661 · Cited by 23
TRPV1: A novel target for the therapy of diabetes and diabetic complications
Shen, Y.-R., Cheng, L., & Zhang, D. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177021 · Cited by 22
Metabolic Modulators in Depression: Emerging Molecular Mechanisms and Therapeutic Opportunities
Dyndał, K., Pańczyszyn-Trzewik, P., & Sowa-Kućma, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178755 · Cited by 19
Witaszek, T., Kłoda, K., Mastalerz–Migas, A., & Babicki, M. (2024) · Nutrients · doi:10.3390/nu16152438 · Cited by 19
Linking the reversal of gestational insulin resistance to postpartum depression
Abeysekera, M. V., Ni, D., Gilbert, L., Hibbert, E., & Nanan, R. K. H. (2024) · BMC Medicine · doi:10.1186/s12916-024-03659-7 · Cited by 17
Masuda, Y., Ohbayashi, K., & Iwasaki, Y. (2025) · Diabetology International · doi:10.1007/s13340-025-00819-9 · Cited by 17
Yeung, A. W. K., Hammerle, F. P., Behrens, S., Matin, M., Mickael, M., Litvinova, O., Parvanov, E. D., Kletečka-Pulker, M., & Atanasov, A. G. (2025) · JMIR Infodemiology · doi:10.2196/59767 · Cited by 15
GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective
d’Ávila, M., Hall, S., & Horváth, T. L. (2024) · Endocrinology · doi:10.1210/endocr/bqae128 · Cited by 14
Dumiaty, Y., Underwood, B. M., Phy‐Lim, J., & Chee, M. J. S. (2024) · Neuropeptides · doi:10.1016/j.npep.2024.102427 · Cited by 13
Carminati, M., Tondello, M., Concina, A., Olgiati, P., & Zanardi, R. (2025) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000595 · Cited by 13
Xiang, L., & Peng, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062741 · Cited by 13
Seetharaman, S., & Cengiz, E. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241305641 · Cited by 10
Seetharaman, S., & Cengiz, E. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241309896 · Cited by 9
Zhang, Z., Li, S., Dai, X., Li, C., Pengfei, S., Qu, J., Jiang, H., & Pan, B. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119509 · Cited by 9
Hemiplegic Migraines Exacerbated using an Injectable GLP-1 Agonist for Weight Loss
Modestino, E. J., Bowirrat, A., Lewandrowski, K., Sharafshah, A., Badgaiyan, R. D., Thanos, P. K., Baron, D. A., Dennen, C. A., Elman, I., Sunder, K. R., et al. (2024) · Acta Scientific Neurology · doi:10.31080/asne.2024.07.0731 · Cited by 8
Stojkovska, A., Prelog, P. R., & Palandačić, A. K. (2025) · Journal of International Medical Research · doi:10.1177/03000605251349393 · Cited by 7
Salerno, E., Fumarulo, I., Garramone, B., Vaccarella, M., Ierardi, C., Burzotta, F., & Aspromonte, N. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.103213 · Cited by 6
Ameer, F., Villacres, N. Y., Bustos, D., Shah, P., Appah, N., Luzaya, G. N., Corradi, F., Bakare, I. S., Trujillo, J. V., Mylavarapu, M., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01770-x · Cited by 5
Progress and challenges in obesity pharmacotherapy: semaglutide as a milestone
Ferrara, F., Bazzani, D., Crivelli, B., Danieli, E., Gazzola, P., Guarnieri, G., Handschin, G., Lauria, C., Marchetti, C., Sbraga, E., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04319-0 · Cited by 4
Kim, J.-W. (2025) · Journal of Yeungnam Medical Science · doi:10.12701/jyms.2025.42.61 · Cited by 4
Central nervous system stimulants and drugs that suppress appetite
Akgün, E. E., Uzumcu, M., & Bello, N. T. (2024) · Side effects of drugs annual · doi:10.1016/bs.seda.2024.09.003 · Cited by 4
Side effects of medications used in the management of diabetes
D’Souza, M. S., Salamie, H., Krmic, M., Slezak, B., & Ray, S. D. (2024) · Side effects of drugs annual · doi:10.1016/bs.seda.2024.07.019 · Cited by 4
Ye, L., Tang, P., Wan, H., Zhong, X., Chen, X., Liu, C., & Huang, R. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s581491 · Cited by 3
Mental Health Factors in Semaglutide Discontinuation
Endo, M., & Kami, M. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.8390 · Cited by 3
GLP-1 receptor agonists in addiction and affective disorders: Implications for dual disorders
Seijas‐Amigo, J., Salgado‐Barreira, Á., Eiras, S., Arias-Rivas, S., Rodríguez-Carnero, G., & González‐Juanatey, J. R. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111802 · Cited by 3
GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns
Nowak, K., Łupina, K., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00459-w · Cited by 2
Hofstad, M., & Abreu, I. D. (2026) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000920 · Cited by 2
Yaghmayee, S., Moazzeni, A. S., Jamialahmadi, T., Karav, S., Yaribeygi, H., Kesharwani, P., & Sahebkar, A. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.06.009 · Cited by 2
Semaglutide and GLP-1 Agonists: Forensic and Medicolegal Implications
Fagiola, M. (2025) · American Journal of Forensic Medicine & Pathology · doi:10.1097/paf.0000000000001044 · Cited by 2
Effects of semaglutide on mental health
Rozhdestvenskaya, V. A., Iuzbashian, P. G., Romanov, D. V., Shchurenkov, A. V., Kazaryan, P. A., Sheyanov, A. M., Zubacheva, E. O., & Fedyainova, I. K. (2025) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202512509128 · Cited by 1
Ji, W., Ma, Y., Fang, J., & Chen, L. (2026) · Endocrine Connections · doi:10.1530/ec-25-0403 · Cited by 1
Alanazi, A. S., & Alanazi, B. A. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1893173 · Cited by 1
Semaglutide – a long – awaited cure for obesity or an elusive treatment?
Oleksak, I., Maliszewska, K., Szawłoga, T., Welian-Polus, I., Wilanowska, W., Babkiewicz-Jahn, K., Matuszewska, J., Szymańska, A., & Independent Public Health Care Facility in Puławy, P. (2024) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2024.4.3 · Cited by 1
Semaglutide-associated psychiatric disorders: A case report and literature review
Escolà‐Rodríguez, A., de Andrés, B., Hervis, T., & Rovira-Illamola, M. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2025.501613
Kır, Y., Haymana, C., Torus, B., Güler, B. Y., Uflaz, B., Eroğlu, G., Gursoy, A., Boyraz, E., Akkan, T., Akın, Ş., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03024-w
Cai, J., Dai, S., Shao, P., & Wu, R. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-04982-x
Semaglutide-associated psychiatric disorders: A case report and literature review
Escolà‐Rodríguez, A., de Andrés, B., Hervis, T., & Rovira-Illamola, M. (2025) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2025.501613
Makowska, K., Billewicz, M., Marczyk, A., & Lis, L. (2024) · Quality in Sport · doi:10.12775/qs.2024.20.54194
Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review
Chan, T. H., Cosler, L. E., Gionfriddo, M. R., Leppien, E. E., Sommers, E. J., & Lussier, M. E. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70878
Zhou, J., Zheng, Y., Xu, B., Long, S., Zhu, L.-E., Liu, Y., Li, C., Zhang, Y., Liu, M., & Wu, X. (2024) · Figshare · doi:10.6084/m9.figshare.26680684
Mental Health After Childbirth in Women with Previous Bariatric Surgery: The SPOtMom Pilot Study
Plank, U. C., Wehrmann, K., Oehlhof, F., Teske, E., Stier, C. K., Seyfried, F., Buchholz, W., Warrings, B., Faßnacht, M., Kübler, A., et al. (2025) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2515-3240
Lenham, R. K., Elgammal, F., Harding, S., & Berry, M. D. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_821
Chen, Z., Zhou, Y., Li, G., MUTHANNA, A., d’Arqom, A., Tham, C. L., Ho, Y.-C., & Lee, M. T. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02110-3
The safety of semaglutide in patients with depression and obesity
Yang, Z., & Yan, Y. (2024) · Obesity · doi:10.1002/oby.24142
Jani, H. T., Levine, H., Patel, A., Trivedi, R., & Patel, X. D. (2026) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10585
Semaglutide and Exacerbation of Psychogenic Non-Epileptic Activity: A Case Report
Fusick, A. J. (2026) · Journal of Psychiatric Insight Review · doi:10.63721/26jpir0132
New-onset depersonalization–derealization syndrome following semaglutide therapy
Prasad, S., Sharma, A., Sharma, A., Parmar, V., Kothia, D., & Bavaria, D. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag367
Semaglutide: Various toxicity: 2 case reports
(2023) · Reactions Weekly · doi:10.1007/s40278-023-47344-4
Metadata
- Authors
- Li, J.-R., Cao, J., Wei, J., & Geng, W.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Cao, Jinya
- Wei, Jing
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2023-08-29
- Volume
- 14
- Pages
- 1238353-1238353
- ISSN
- 1664-0640 (ISSN-L)
- PMC
- PMC10495976
- OpenAlex
- W4386246639
- Cited by
- 50
- References
- 22
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 18 · 2023: 2
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Peking Union Medical College Hospital
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- semaglutide, depression, psychiatric adverse effects, GLP-1 receptor agonists, type 2 diabetes, weight loss, recurrent depression, drug discontinuation, antidepressant effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

